Cytokines / Hematopoietic agents / Megakaryocyte growth factors
Megakaryocyte growth factors
Mechanism of action
- INTERLEUKIN 11 (the recombinant form is called OPRELVEKIN) and THROMBOPOIETIN increase platelet production
- autoantibodies form after infusion of recombinant forms of THROMBOPOIETIN
- ROMIPLOSTIM is a nonimmunogenic peptide agonist of the thrombopoietin receptor (Mpl)
- it is the first approved "peptibody"
- two Mpl-binding peptides were linked to human Fc fragments
Pharmacokinetics
- ROMIPLOSTIM has a half-life of 3-4 days
- longer t1/2 in patients with thrombocytopenia; shorter in patients whose platelet counts have recovered
Therapeutic Uses
- thrombocytopenia, particularly following chemotherapy
- idiopathic thrombocytopenia (ITP)
Side effects
INTERLEUKIN 11
LIFE-THREATENING: |
|
|
---|---|---|
SERIOUS | INNOCUOUS | |
COMMON |
|
|
RARE |
|
|
|
ROMIPLOSTIM
- well tolerated except for mild headache on the day of administration